Johnson & Johnson (JNJ)

JNJ on New York Consolidated

98.18USD
1 Jul 2015
Change (% chg)

$0.72 (+0.74%)
Prev Close
$97.46
Open
$98.30
Day's High
$98.68
Day's Low
$97.64
Volume
2,879,522
Avg. Vol
7,645,408
52-wk High
$109.49
52-wk Low
$95.10

JNJ

Chart for JNJ

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and... (more)

Overall

Beta: 0.56
Market Cap(Mil.): $270,261.00
Shares Outstanding(Mil.): 2,773.04
Dividend: 0.75
Yield (%): 3.08

Financials

  JNJ Industry Sector
P/E (TTM): 17.45 35.50 39.29
EPS (TTM): 5.59 -- --
ROI: 14.86 17.07 16.27
ROE: 22.04 17.96 17.40
Search Stocks

MDL sought for Johnson & Johnson power morcellator lawsuits

- Lawyers for six women suing Johnson & Johnson over injuries allegedly caused by its power morcellator medical devices have sought to consolidate more than 20 similar lawsuits in Kansas federal court.

22 Jun 2015

U.S. current account widens on weak exports, overseas profits

WASHINGTON - The U.S. current account deficit widened in the first quarter to its highest level since 2012 likely due to the strong dollar's drag on overseas profits and exports.

18 Jun 2015

U.S. industrial output hurt by weakness in manufacturing, mining

WASHINGTON - U.S. industrial production unexpectedly fell in May as manufacturing and mining activity remained weak, a sign that a strong dollar and spending cuts in the energy sector continued to constrain economic growth.

15 Jun 2015

WRAPUP 2-U.S. industrial output hurt by weakness in manufacturing, mining

WASHINGTON, June 15 - U.S. industrial production unexpectedly fell in May as manufacturing and mining activity remained weak, a sign that a strong dollar and spending cuts in the energy sector continued to constrain economic growth.

15 Jun 2015

Genmab shares rise on cancer drug's FDA licence application

COPENHAGEN, June 8 - Shares in Genmab rose almost 3 percent on Monday after partner Johnson and Johnson's announcement late on Friday that the companies have applied to U.S. authorities for a licence to market their blood cancer drug daratumumab.

08 Jun 2015

U.S. economy contracts in first quarter; dollar hurts corporate profits

WASHINGTON - The U.S. economy contracted in the first quarter as it buckled under the weight of unusually heavy snowfalls, a resurgent dollar and disruptions at West Coast ports, but activity already has rebounded modestly. | Video

29 May 2015

WRAPUP 4-U.S. economy contracts in Q1; dollar hurts corporate profits

WASHINGTON, May 29 - The U.S. economy contracted in the first quarter as it buckled under the weight of unusually heavy snowfalls, a resurgent dollar and disruptions at West Coast ports, but activity already has rebounded modestly.

29 May 2015

FBI probing what J&J knew about uterine surgery device: WSJ

- The Federal Bureau of Investigation is probing a surgical tool found to spread uterine cancer and what Johnson & Johnson knew about its risks before withdrawing its version of the device last year, the Wall Street Journal reported.

27 May 2015

UPDATE 1-FBI probing what J&J knew about uterine surgery device - WSJ

May 27 - The Federal Bureau of Investigation is probing a surgical tool found to spread uterine cancer and what Johnson & Johnson knew about its risks before withdrawing its version of the device last year, the Wall Street Journal reported.

27 May 2015

J&J to submit at least 10 new drugs for approval by 2019

- U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

20 May 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks